Conference report highlights advances in cytokine-induced killer cell therapies, suggesting expanded clinical potential for engineered cell treatments.
On April 7, 2025, the 2nd International CIK Cell Conference was held in Monza, Italy, marking the establishment of the International Society for CIK Cells (ISCC). The conference, kindly supported by Fondazione Tettamanti (Italy), featured cutting-edge advancements in cytokine-induced killer (CIK) cell immunotherapy, used alone and in combination with dendritic cells (DC-CIK) and chimeric antigen receptors (CAR-CIK). The event also provided a valuable opportunity for young investigators to engage in insightful discussions and to network within experts in the field.
No takes yet. Share an insight, caveat, or question.
Sangiolo et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: